Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

• Positive and Negative Syndromes Scale (PANSS) total score at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
  
  
• Positive and Negative Syndromes Scale (PANSS) total score at Week 2 [ Time Frame: Week 2 ] [ Designated as safety issue: No ]
  The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
  
  
• Positive and Negative Syndromes Scale (PANSS) total score at Week 4 [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
  The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
  
  
• Positive and Negative Syndromes Scale (PANSS) total score at Week 8 [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
  
  
• Positive and Negative Syndromes Scale (PANSS) total score at Week 16 [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
  The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
  
  
• Positive and Negative Syndromes Scale (PANSS) total score at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
  
  

• Clinical Global Impressions (CGI) - Disease Severity score [ Time Frame: Baseline up to Week 24 ] [ Designated as safety issue: No ]
  The CGI rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
  
  
• Extrapyramidal Symptoms Rating Scale (ESRS) total score [ Time Frame: Baseline up to Week 24 ] [ Designated as safety issue: Yes ]
  The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe).
  
  
• Drug Attitude Inventory (DAI-10) [ Time Frame: Screening up to Week 24 ] [ Designated as safety issue: Yes ]
  The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant).
  
  
• Short Form-36 (SF-36) - Quality of life [ Time Frame: Screening up to Week 24 ] [ Designated as safety issue: No ]
  The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.
  
  

This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of risperidone in participants with schizophrenia who have a previous history (in the last 12 months) of bad adherence to the antipsychotic treatment of first or second oral generation. The duration of this study will be 24 weeks and will include following visits: Screening, Baseline, Week 2, 4, 8, 12, 16, 20 and 24 (End visit or early withdrawal). All the eligible participants (after risperidone intolerance test during screening) will receive a dose of 25 milligram risperidone every two weeks by intramuscular injection (injection of a substance into a muscle). Efficacy and safety of the participants will primarily be evaluated by Positive and Negative Syndromes Scale and Extrapyramidal Symptom Rating Scale, respectively. Participants' safety will be monitored throughout the study.